Oncological outcomes from trimodality therapy receiving definitive doses of neoadjuvant chemoradiation (≥60 Gy) and factors influencing consideration for surgery in stage III non-small cell lung cancer.
Vyfhuis, Melissa A L
Oncological outcomes from trimodality therapy receiving definitive doses of neoadjuvant chemoradiation (≥60 Gy) and factors influencing consideration for surgery in stage III non-small cell lung cancer. [electronic resource] - Advances in radiation oncology - 259-269 p. digital
Publication Type: Journal Article
2452-1094
10.1016/j.adro.2017.07.009 doi
Oncological outcomes from trimodality therapy receiving definitive doses of neoadjuvant chemoradiation (≥60 Gy) and factors influencing consideration for surgery in stage III non-small cell lung cancer. [electronic resource] - Advances in radiation oncology - 259-269 p. digital
Publication Type: Journal Article
2452-1094
10.1016/j.adro.2017.07.009 doi